US biobased specialty chemical company DMC Biotechnologies Inc (DMC) has announced that has completed downstream processing for its first product, the amino acid L-alanine. The downstream processing was done at EW Biotech GmbH's facilities in Leuna, Germany following the successful demonstration of commercial-scale fermentation at the same site in March this year.
The purification of L-alanine from the fermentation broth was successfully completed for more than 6 tonnes of product. Product release testing has demonstrated that rigorous customer specifications for L-alanine were met.
Demonstration of the purification process and achievement of product specifications is the final proof point for DMC’s approach to producing L-alanine.
It was a demanding project at a very unusual time. Preparations for the downstream processing (DSP) implementation in our facility went in parallel to the fermentation scale-up activities. With the deep contributions from our network of long-term partners, we were able to deliver product that met target specifications. Thanks to DMC and our operating team at EW Biotech for making this project a joint success, said Dr-Ing Markus Fritsch, Senior Project Manager at EW Biotech.
As announced last month, L-alanine is now available at a commercial scale following the execution of a manufacturing agreement with Conagen.
We recently announced the successful full commercial-scale demonstration of our fermentation process. Historically, fermentation scale-up has been a major stumbling block for early-stage companies. Delivering products to customers also requires successful purification and demonstration that the product meets the required specifications. We now have product with demonstrated quality metrics enabling customer adoption, said Dr Matt Lipscomb, CEO and Co-Founder of DMC.